Clinical utility of hepatitis C virus core antigen assay in the monitoring of direct-acting antivirals for chronic hepatitis C

Citation metadata

From: PLoS ONE(Vol. 15, Issue 3)
Publisher: Public Library of Science
Document Type: Article
Length: 3,367 words
Lexile Measure: 1520L

Document controls

Main content

Abstract :

Background Hepatitis C virus core antigen (HCV Ag) assay has been proposed as a more economical alternative to HCV RNA detection. This study aimed to investigate the clinical utility of HCV Ag assay in the monitoring of direct-acting antivirals (DAAs) for chronic hepatitis C patients. Methods We analyzed serum samples from 110 patients treated with paritaprevir/ritonavir, ombitasvir, and dasabuvir (PrOD) with or without ribavirin. The levels for both HCV Ag and HCV RNA assessed by COBAS TaqMan HCV (CTM) Test or Abbott RealTime HCV (ART) assay were evaluated at baseline, week 2, 4, and 12 during treatment and 12 weeks after completion. Results Baseline HCV Ag levels showed good correlations with HCV viral load (r = 0.879; p Conclusions HCV Ag assay may be a feasible alternative to HCV RNA for the determination of SVR.sub.12 in patients treated with DAAs.

Source Citation

Source Citation   

Gale Document Number: GALE|A616129552